Integra LifeSciences (IART) Tops Q1 EPS by 12c, Updates Guidance

Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.69, $0.12 better than the analyst estimate of $0.57. Revenue for the quarter came in at $360.1 million versus the consensus estimate of $349.81 million.

GUIDANCE:

Integra LifeSciences sees FY2021 EPS of $2.86-$2.93, versus the consensus of $2.90. Integra LifeSciences sees FY2021 revenue of $1.525-1.535 billion, versus the consensus of $1.53 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Morgan Stanley Resumes Urban Outfitters, Inc. (URBN) at Overweight
• Morgan Stanley Downgrades Seven & i Holdings Co Ltd (3382:JP) (SVNDF) to Equalweight, Earnings US May Peak F2/27